secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001628280-25-037603
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics Q2 2025 net loss narrows to $17.9M; cash runway into 2028; pipeline on track
--------------------------------------------------------------------------------

- Net loss of $17.9M in Q2 2025, improved from $23.0M in Q2 2024; collaboration revenue $7.6M.
- Cash, equivalents and marketable securities $198.7M as of June 30, 2025; cash runway into 2028.
- FHD-909 Phase 1 trial in SMARCA4-mutated NSCLC enrolling well; preclinical combo data with pembrolizumab and KRAS inhibitors.
- Selective CBP degrader targeting IND in 2026; selective EP300 and ARID1B degrader updates expected Q4 2025.
- R&D expenses decreased to $21.8M from $23.8M; G&A expenses decreased to $6.9M from $7.3M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828025037603/0001628280-25-037603-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828025037603/fhtx-20250805.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-037603

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer